Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702504 | 0.87 | NPSR1 (0.47) | NPSR1KCNH2EGFRTSHRPOLB | |
| SCHEMBL1293279 | 0.83 | GABRA1 (0.40) | NPSR1KCNH2EGFRTSHRMAPT | |
| SCHEMBL6097246 | 0.83 | TAAR1 (0.47) | NPSR1IDO1RIPK1KCNH2TAAR1 | |
| SCHEMBL9445932 | 0.82 | NPSR1 (0.41) | NPSR1KCNH2EGFRTSHRPOLB | |
| SCHEMBL6384988 | 0.81 | IDO1 (0.42) | IDO1RIPK1TSHRTAAR1MAPT | |
| SCHEMBL18157311 | 0.80 | LMNA (0.38) | NPSR1KCNH2EGFRTSHRPOLB | |
| SCHEMBL12212067 | 0.80 | NPSR1 (0.42) | NPSR1KCNH2EGFRTSHRPOLB | |
| SCHEMBL916350 | 0.80 | CCNT1 (0.43) | NPSR1KCNH2EGFRTSHRTAAR1 | |
| SCHEMBL3373620 | 0.79 | MAPT (0.44) | NPSR1KCNH2EGFRTSHRPOLB | |
| SCHEMBL10022793 | 0.79 | MAPT (0.44) | NPSR1KCNH2EGFRTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025237891-A1 | QUINOLINE-2-CARBOXAMIDE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-11-20 | — | — | WO | disclosed |
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2013061247-A1 | NOVEL PROCESS FOR THE PREPARATION OF ASENAPINE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2013-05-02 | — | — | WO | disclosed |
| US-8227623-B2 | Process for the preparation of asenapine and intermediate products used in said process | MSD OSS B.V. (NL) | 2012-07-24 | — | — | US | disclosed |
| US-8227623-B2 | Process for the preparation of asenapine and intermediate products used in said process | MSD OSS B.V. (NL) | 2012-07-24 | — | — | US | disclosed |
| US-8227623-B2 | Process for the preparation of asenapine and intermediate products used in said process | MSD OSS B.V. (NL) | 2012-07-24 | — | — | US | disclosed |
| EP-2240492-B1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-07-07 | — | — | US | disclosed |
| US-7964739-B2 | Through a stilbene derivative, to a pyrrolidine intermediate, followed by cyclization; asenapine is an antipsychotic agent; industrial scale | N.V. ORGANON (NL) | 2011-06-21 | — | — | US | disclosed |
| WO-2011012654-A1 | HYDROXYASENAPINE COMPOUNDS, DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | N.V. ORGANON (NL) | 2011-02-03 | — | — | WO | disclosed |
| CN-1886376-A | Pyridine compounds as dipeptidyl dipeptidase-IV inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| EP-1423356-A2 | NOVEL AMINOBENZOEPHENONES | Leo Pharma A/S (DK) | 2004-06-02 | — | — | EP | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
| EP-0934312-B1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK AS (DK) | 2003-03-19 | — | — | EP | disclosed |
| WO-2003018535-A2 | NOVEL AMINOBENZOEPHENONES | LEO PHARMA A/S (DK) | 2003-03-06 | — | — | WO | disclosed |
| EP-0934312-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015548-A1 | 1,4-DISUBSTITUTED PIPERAZINES | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| US-5242908-A | Of dna and rna | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-07 | — | — | US | disclosed |
| EP-0440148-A1 | Use of benzylphosphonic acid derivates for the treatment of viral diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | NPSR1 1291/4885IDO1 1762/4885RIPK1 2218/4885 |
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | CYP3A5, QDPR, SPR | NPSR1 843/4885IDO1 3361/4885RIPK1 3088/4885 |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | NPSR1 3079/4885IDO1 323/4885RIPK1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.